Searched for: subject:"Animals"
(1 - 11 of 11)
document
Zacharowski, K. (author), Zacharowski, P.A. (author), Friedl, P. (author), Mastan, P. (author), Koch, A. (author), Boehm, O. (author), Rother, R.P. (author), Reingruber, S. (author), Henning, R. (author), Emeis, J.J. (author), Petzelbauer, P. (author), TNO Kwaliteit van Leven (author)
Many compounds have been shown to prevent reperfusion injury in various animal models, although to date, translation into clinic has revealed several obstacles. Therefore, the National Heart, Lung, and Blood Institute convened a working group to discuss reasons for such failure. As a result, the concept of adequately powered, blinded, randomized...
article 2007
document
Zadelaar, A.S.M. (author), Boesten, L.S.M. (author), Jukema, J.W. (author), van Vlijmen, B.J.M. (author), Kooistra, T. (author), Emeis, J.J. (author), Lundholm, E. (author), Camejo, G. (author), Havekes, L.M. (author), Gaubius Instituut TNO (author)
OBJECTIVE - We investigated whether the dual PPARα/γ agonist tesaglitazar has anti-atherogenic effects in ApoE*3Leiden mice with reduced insulin sensitivity. METHODS AND RESULTS - ApoE*3Leiden transgenic mice were fed a high-fat (HF) insulin-resistance-inducing diet. One group received a high-cholesterol (HC) supplement (1% wt/wt; HC group). A...
article 2006
document
Trion, A. (author), de Maat, M.P.M. (author), Jukema, J.W. (author), van der Laarse, A. (author), Maas, M.C. (author), Offerman, E.H. (author), Havekes, L.M. (author), Szalai, A.J. (author), Princen, H.M.G. (author), Emeis, J.J. (author), TNO Kwaliteit van Leven (author)
Objective - C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development of atherosclerosis. Mouse CRP is not expressed at high levels under normal conditions and increases in concentration only several-fold during an acute phase response. Because the...
article 2005
document
Verschuren, L. (author), Kleemann, R. (author), Offerman, E.H. (author), Szalai, A.J. (author), Emeis, S.J. (author), Princen, H.M.G. (author), Kooistra, T. (author), TNO Kwaliteit van Leven (author)
Objective - To evaluate whether low-dose atorvastatin suppresses atherosclerotic lesion progression and inflammation in apolipoprotein E*3 (apoE*3)-Leiden mice beyond its cholesterol-lowering effect. Methods and Results - ApoE*3-Leiden mice were fed a high-cholesterol (HC) diet until mild atherosclerotic lesions had formed. Subsequently, HC diet...
article 2005
document
Kleemann, R. (author), Princen, H.M.G. (author), Emeis, J.J. (author), Jukema, J.W. (author), Fontijn, R.D. (author), Horrevoets, A.J.G. (author), Kooistra, T. (author), Havekes, L.M. (author)
Background - Statins can exert anti-inflammatory antiatherosclerotic effects through an anti-inflammatory action, independent of lowering cholesterol. We addressed the question whether the anti-inflammatory activities of statins can reduce atherosclerosis beyond the reduction achieved by cholesterol lowering per se. Methods and Results - Two...
article 2003
document
Noorman, F. (author), Barrett-Bergshoeff, M.M. (author), Bekkers, M. (author), Emeis, J.J. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Dextran is used during surgery as a prophylactic agent to prevent deep venous thrombosis. Recently it has been shown that dextran increases t-PA plasma concentrations in patients. As dextran is a potential ligand for the mannose receptor, we studied whether this glucose-polymer would be able to inhibit mannose receptor-mediated clearance of t-PA...
article 1997
document
Emeis, J.J. (author), van den Hoogen, C.M. (author), Gaubius Laboratory IVVO-TNO, P.O. Box 430, 2300 AK Leiden, Netherlands Instituut voor verouderings- en vaatziekten onderzoek TNO (author)
Pharmacological modulation of the in vivo induction of plasminogen activator inhibitor type-1 (PAI-1) synthesis was studied in rats using the induction of PAI-1 by endotoxin as a model system. Both the cyclooxygenase inhibitors acetylsalicylic acid and indomethacin enhanced PAI-1 induction. The combined cyclooxygenase-lipoxygenase inhibitor,...
article 1992
document
Emeis, J.J. (author), Verheijen, J.H. (author), Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)
Chemicals/CAS: Recombinant Proteins; Tissue Plasminogen Activator, EC 3.4.21.68
article 1992
document
van Pelt-Verkuil, E. (author), van de Ree, P. (author), Emeis, J.J. (author), Gaubius Institute TNO, 2300 AP Leiden, Netherlands (author)
The effects of lowering plasma fibrinogen levels by Arvin injections have been investigated in a rat model of arteriosclerosis. In this model air-drying-induced endothelial denudation of the left carotid artery results in myointimal lesion development. Arvin (2 x 50 Units/kg) was given at 4 and 2 hours prior to surgery, reducing plasma...
article 1989
document
van Hinsbergh, V.W.M. (author), Kooistra, T. (author), van den Berg, E.A. (author), Princen, H.M.G. (author), Fiers, W. (author), Emeis, J.J. (author), Gaubius instituut TNO (author)
The vascular endothelium plays an important role in fibrinolysis by producing tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI). The monokine tumor necrosis factor (human recombinant TNF) increased the production of PAI by cultured human endothelial cells from umbilical vein (twofold) and from foreskin...
article 1988
document
Emeis, J.J. (author), Kluft, C. (author), Gaubius instituut TNO (author)
Platelet-activating factor (PAF-acether; 1-O-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) induced the release of plasminogen activator in rat, both in vivo and in perfused hind legs. The released plasminogen activator was shown by immunologic and functional criteria to be tissue-type plasminogen activator (t-PA). Release of t-PA by PAF...
article 1985
Searched for: subject:"Animals"
(1 - 11 of 11)